Epigenetic drug screen identifies the histone deacetylase inhibitor NSC3852 as a potential novel drug for the treatment of pediatric acute myeloid leukemia.
Caroline R M WiggersAnita M A P GoversDaphne LelieveldDavid A EganChristian Michel ZwaanEdwin SonneveldPaul J CofferMarije BartelsPublished in: Pediatric blood & cancer (2019)
NSC3852 is a potential candidate drug for further preclinical testing in pediatric AML and DS-AMKL.